+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Retinitis Pigmentosa (Retinitis) Disease - Global Clinical Trials Review, H2 2020

  • ID: 5187138
  • Clinical Trials
  • October 2020
  • Region: Global
  • 108 Pages
  • GlobalData
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • AbbVie Inc
  • CMAX
  • Dompe Farmaceutici SpA
  • Horama SA
  • jCyte Inc
  • Neurotech Holdings LLC
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's clinical trial report, “Retinitis Pigmentosa (Retinitis) Disease - Global Clinical Trials Review, H2, 2020“. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • CMAX
  • Dompe Farmaceutici SpA
  • Horama SA
  • jCyte Inc
  • Neurotech Holdings LLC

Report Guidance
  • Clinical Trials Report Coverage

Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Retinitis Pigmentosa (Retinitis) to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Retinitis Pigmentosa (Retinitis) to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase
  • In Progress Trials by Phase

Clinical Trials by Trial Status
Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials

Prominent Drugs
  • Clinical Trial Profile Snapshots

Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About the Publisher
  • Contact
  • Source

List of Tables
  • Retinitis Pigmentosa (Retinitis) Therapeutics, Global, Clinical Trials by Region, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Europe, Top Five Countries, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, North America, Top Countries, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Central and South America, Top Countries, 2020*
  • Proportion of Retinitis Pigmentosa (Retinitis) to Ophthalmology Clinical Trials, G7 Countries (%), 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Retinitis Pigmentosa (Retinitis) to Ophthalmology Clinical Trials, E7 Countries (%), 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, Global, Clinical Trials by Phase, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, Global, Clinical Trials In Progress by Phase 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Retinitis Pigmentosa (Retinitis) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*

List of Figures
  • Retinitis Pigmentosa (Retinitis) Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2020*
  • Proportion of Retinitis Pigmentosa (Retinitis) to Ophthalmology Clinical Trials, G7 Countries (%), 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Retinitis Pigmentosa (Retinitis) to Ophthalmology Clinical Trials, E7 Countries (%), 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, Global, Clinical Trials by Phase (%), 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Retinitis Pigmentosa (Retinitis) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Retinitis Pigmentosa (Retinitis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
  • Methodology
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Novelion Therapeutics Inc
  • AbbVie Inc
  • Neurotech Holdings LLC
  • Applied Genetic Technologies Corp
  • Horama SA
  • jCyte Inc
  • Ocugen Inc
  • ReNeuron Group Plc
  • CMAX
  • Dompe Farmaceutici SpA
Note: Product cover images may vary from those shown